Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma

Fig. 1

Whole-body maximum intensity projection (MIP) images are shown of a representative participant with HNC, CRC, or NHL. The [18F]FDG PET images (front and side views) are shown on the left, and the [18F]FSPG PET images (front and side views) are shown on the right. Red arrows indicate sites of malignancy on each scan

Back to article page